Table of Contents Table of Contents
Previous Page  111 / 812 Next Page
Information
Show Menu
Previous Page 111 / 812 Next Page
Page Background

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S72–S115

S107

Aims

(1) To compare hospitalization rates of patients stabilized

on treatment with LAIs and CLZ. (2) To determine whether treat-

ment with LAIs and CLZ within CP can influence hospitalization

rates.

Methods

Data were retrospectively collected from patients diag-

nosed with non-affective psychoses with FA between 2000 and

2014; 200 patients were then divided into three groups, according

to stabilized treatment regimen during the final year of observa-

tion: treatment as usual (TAU), CLZ, LAIs. hospitalization duration

(HSPD) and frequency (HSP) were calculated for each group.

Results

Despite a major severity before assignment to either CLZ

or LAIs treatment, HSPD and HSP in both groups shifted below

those observed for the TAU arm. Patients who began treatment

with LAIs within the CP showed a highly significant decrease of

both HSPD and HSP (respectively 17.4

±

18 vs. 2.6

±

8.2; Z =

2.856;

P

< 0.005 and 1.1

±

0.8 vs. 0.2

±

0.5; Z =

3.115;

P

< 0.005). No signif-

icant changes in hospitalization rates were observed for subjects

who began treatment with LAIs after the CP.

Conclusions

Our study confirms that treatment with either CLZ

or LAIs significantly impacts the course of psychotic disorders. The

data seem to suggest that LAIs and CLZ should be considered more

effective than conventional oral antipsychotics in the early-stages

of psychotic illness. The difference among treatments tends towane

beyond the CP, especially for LAIs.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.088

FC85

Metabolic syndrome in patients with

schizophrenia receiving long-term

treatment with lurasidone, quetiapine

XR, or risperidone

J. Newcomer

1 , M.

Tocco

2 , A.

Pikalov

3 ,

, H .

Zheng

3 , J. C

ucchiaro

3 ,

A. Loebel

3

1

Florida Atlantic University Charles E. Schmidt College of Medicine,

N/A, Boca Raton, USA

2

Sunovion Pharmaceuticals Inc., N/A, Marlborough, USA

3

Sunovion Pharmaceuticals Inc., N/A, Fort Lee, USA

Corresponding author.

Introduction

Lurasidone has demonstrated low propensity for

metabolic disturbance in adult patients with schizophrenia in

short-term studies.

Objectives

To evaluate metabolic syndrome occurrence during

long-term lurasidone treatment in patients with schizophrenia.

Aims

To comparemetabolic syndrome rates with lurasidone ver-

sus other antipsychotic agents.

Methods

Metabolic syndrome rates (as defined by the US

National Cholesterol Education Program-Adult Treatment Panel

III) were evaluated in adult patients with schizophrenia treated

with lurasidone in 2 long-term, active-controlled studies (queti-

apine XR or risperidone). In the quetiapine XR-controlled study,

patients completing a 6-week, double-blind, placebo-controlled,

fixed-dose trial of lurasidone (74mg/d or 148mg/d) or quetiapine

XR (600mg/d) continued on double-blind, flexibly dosed lurasi-

done (37–148mg/d) or quetiapine XR (200–800mg/d) for up to

12 months. In the risperidone-controlled study, patients received

double-blind, flexibly dosed lurasidone (37–111mg/d) or risperi-

done (2–6mg/d) for up to 12 months.

Results

Among patients without metabolic syndrome at base-

line in the quetiapine XR-controlled study, 2.4% (2/84) of

lurasidone-treated patients and 7.4% (2/27) of quetiapine XR-

treated patients developed metabolic syndrome at month 12

(

P

=NS). Of patients without metabolic syndrome at baseline in the

risperidone-controlled study, 10.3% (12/117) and 23.2% (16/69) of

lurasidone- and risperidone-treated patients, respectively, devel-

oped metabolic syndrome at month 12 (

P

= 0.02).

Conclusions

Long-term treatment with lurasidone was associ-

ated with lower rates of metabolic syndrome in patients with

schizophrenia compared to treatment with quetiapine XR or

risperidone.

Support

Sunovion Pharmaceuticals Inc.

ClinicalTrials.gov identifiers

NCT00789698, NCT00641745.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.089

FC86

Neurochemical and behavioral

sensitization to d-amphetamine in

healthy subjects measured with

[

11

C]-(+)-PHNO-PET

A. Popovic

1 ,

, M. Bauer

2

, L. Bartova

1

, U. Sauerzopf

1

,

N. Praschak-Rieder

1

, C. Rami-Mark

3

, L. Nics

3

, C. Philippe

3

,

M. Mitterhauser

3

, W. Wadsak

3

, S. Kasper

1

, M. Willeit

1

1

Medical University of Vienna, Department of Psychiatry and

Psychotherapy, Vienna, Austria

2

Medical University of Vienna, Department of Clinical Pharmacology,

Vienna, Austria

3

Medical University of Vienna, Department of Nuclear Medicine,

Vienna, Austria

Corresponding author.

Introduction

It has been shown that patients with schizophre-

nia are super-sensitive towards dopamine-releasing agents such as

amphetamine. Here, we studied the effects of amphetamine sen-

sitization on amphetamine-induced dopamine release in healthy

subjects.

Objectives

To measure d-amphetamine-induced dopamine

release as measured with the D

2,3

agonist radioligand [

11

C]-(+)-

PHNO-PET via change in non-displacable binding potential (BP

ND

)

and behavioral measures of d-amphetamine effects with drug

effects questionnaire (DEQ) and subjective states questionnaire

(SSQ).

Aims

To study d-amphetamine-induced sensitization in healthy

subjects on a behavioral and neurochemical level with [

11

C]-(+)-

PHNO-PET in order to gain more knowledge on sensitization-

induced changes in the dopaminergic system.

Methods

Twelve stimulant-naïve healthy male subjects under-

went three 90-min [

11

C]-(+)-PHNO-PET-scans and four oral

administrations of d-amphetamine. After a naïve baseline scan,

subjects underwent a PET scanwith previous ingestion of 0.4mg/kg

bodyweight of d-amphetamine 90–120minutes before scanning.

Subsequently, subjects were sensitized to d-amphetamine with

the same dose on two separate days. Thereafter, they underwent

another PET scanwith previous d-amphetamine ingestion. DEQand

SSQ were administered before, 60min, 90–120min, and 210min

after amphetamine ingestion.

Results

We found significant sensitization effects on a behavioral

level and on a neurochemical level after four administrations of

amphetamine. Items of the SSQ, which showed significant sensi-

tization effects were “outgoing”, “energetic”, “lively”, “alert” and

“focused”.

Conclusions

We were able to induce significant behavioral and

neurochemical sensitization in healthy humans, which were mea-

sured with [

11

C]-(+)-PHNO-PET for the first time. This sensitization

model will be useful for studying the neurobiology of schizophre-

nia.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.090